Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Masitinib in non pre-treated GIST
NCT00998751Phase 2Completed
- Sponsor
- AB Science
- Start
- Jun 2005
- Primary completion
- Jun 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of masitinib in gastrointestinal stromal tumor (GIST), sponsored by AB Science. Primary endpoint: Objective Response Rate at 2 months. Started Jun 2005; status: completed.
02
Drugs
masitinib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT00998751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00998751.